References

1. Proft F, Poddubnyy D. Ankylosing spondylitis and axial spondyloarthritis: Recent insights and impact of new classification criteria. Ther Adv Musculoskelet Dis 2018;10(5-6):129-139. https://doi. org/10.1177/1759720X18773726
2. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3(1):55-78. https://doi. org/10.1016/0049-0172(73)90035-8
3. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Arch Dermatol 2005;141(12):1537-1541. https://doi.org/10.1001/archderm.141.12.1537
4. Brandrup F, Green A. The prevalence of psoriasis in Denmark. Acta Dermato-Venereologica 1981;61(4):344-346.
5. Ferrándiz C, Bordas, Puig S, Pujol R, Smandía A. Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Euro Acad Dermatol Venereol 2001;15(1):20-23.
6. Zabotti A, de Lucia O, Sakellariou G, et al. Predictors, risk factors, and incidence rates of psoriatic arthritis development in psoriasis patients: A systematic literature review and meta-analysis. Rheumatol Ther 2021;8(4):1519-1534. https://doi.org/10.1007/s40744-021-00378-w
7. Tillett W, Costa L, Jadon D, et al. The ClASsification for Psoriatic ARthritis (CASPAR) criteria – a retrospective feasibility, sensitivity, and specificity study. J Rheumatol 2012;39(1):154-156. https:// doi.org/10.3899/jrheum.110845
8. Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 2016;68(5):1060-1071. https://doi.org/10.3899/jrheum.11084510.1002/art.39573
9. Chandran V, Maharaj AB. Assessing disease activity in psoriasis and psoriatic arthritis: Impact on management and therapy. Expert Rev Clin Immunol 2016;12(5):573-582. https://doi.org/10.1586/17 44666X.2016.1146133
10. Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): Defining remission and treatment success using the DAPSA score. Ann Rheumat Dis 2016;75(5):811-818. https://doi.org/10.1136/annrheumdis-2015-207507
11. Scarpa R, Pucino A. Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report. Acta Dermato-Venereologica 1989;69:69-71.
12. Feldman S, Krueger G. Psoriasis assessment tools in clinical trials. Ann Rheumat Dis 2005;64(Suppl 2):ii65- ii168. https://doi.org/10.1136/ard.2004.031237
13. Farber E, Nall L. Nail psoriasis. Cutis 1992;50(3):174-178.
14. Elkayam O, Ophir J, Yaron M, Caspi D. Psoriatic arthritis: Interrelationships between skin and joint manifestations related to onset, course and distribution. Clin Rheumatol 2000;19:301-305.
15. Williamson L, Dalbeth N, Dockerty J, Gee B, Weatherall R, Wordsworth B. Nail disease in psoriatic arthritis – clinically important, potentially treatable and often overlooked. Rheumatology 2004;43(6):790- 794. https://doi.org/10.1093/rheumatology/keh198
16. Rich P, Scher RK. Nail Psoriasis Severity Index: A useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49(2):206-212. https://doi.org/10.1067/S0190-9622(03)00910-1
17. Cassell SE, Bieber JD, Rich P, et al. The modified Nail Psoriasis Severity Index: Validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007;34(1):123-129.
18. Hanly JG, Russell ML, Gladman D. Psoriatic spondyloarthropathy: A long term prospective study. Ann Rheumat Dis 1988;47(5):386-393.
19. Scarpa R, Oriente P, Pucino A, et al. The clinical spectrum of psoriatic spondylitis. Rheumatology 1988;27(2):133-137. https://doi.org/10.1093/rheumatology/27.2.133
20. Helliwell P, Hickling P, Wright V. Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis? Ann Rheumat Dis 1998;57(3):135-140. https://doi.org/10.1136/ard.57.3.135
21. Helliwell PS, Firth J, Ibrahim GH, Melsom RD, Shah I, Turner DE. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol 2005;32(9):1745-1750.
22. Ritchlin CT. Pathogenesis of psoriatic arthritis. Curr Opinion Rheumatol 2005;17(4):406-412. https:// doi.org/10.1097/01.bor.0000167752.93543.76
23. Gossec L, McGonagle D, Korotaeva T, et al. Minimal disease activity as a treatment target in psoriatic arthritis: A review of the literature. J Rheumatol 2018;45(1):6-13. https://doi.org/10.3899/jrheum.170449
24. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: Results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheumatol 1998;41(6):1103-1110.
25. Bond SJ, Farewell VT, Schentag CT, Gladman DD. Predictors for radiological damage in psoriatic arthritis: Results from a single centre. Ann Rheumat Dis 2007;66(3):370-376. https://doi.org/10.1136/ ard.2006.056457
26. Sheehan NJ. The ramifications of HLA-B27. J Royal Soc Med 2004;97(1):10-14.
27. Panagiotopoulos A, Fragoulis GE. Comorbidities in psoriatic arthritis: A narrative review. Clin Ther 2023;45(2):177-189. https://doi.org/10.1016/j.clinthera.2023.01.006
28. Elmamoun M, Eraso M, Anderson M, et al. International league of associations for rheumatology recommendations for the management of psoriatic arthritis in resource-poor settings. Clin Rheumatol 2020;39:1839-1850. https://doi.org/10.1007/s10067-020-04934-7
29. Sarzi-Puttini P, Santandrea S, Boccassini L, Panni B, Caruso I. The role of NSAIDs in psoriatic arthritis: Evidence from a controlled study with nimesulide. Clin Experiment Rheumatol 2001;19(Suppl 22):S-17.
30. Brenner M, Molin S, Ruebsam K, Weisenseel P, Ruzicka T, Prinz J. Generalised pustular psoriasis induced by systemic glucocorticosteroids: Four cases and recommendations for treatment. Br J Dermatol 2009;161(4):964-966. https://doi.org/10.1111/j.1365-2133.2009.09348.x
31. Gregoire AR, DeRuyter BK, Stratman EJ. Psoriasis flares following systemic glucocorticoid exposure in patients with a history of psoriasis. JAMA Dermatol 2021;157(2):198-201. https://doi.org/10.1001/ jamadermatol.2020.4219
32. Eder L, Chandran V, Ueng J, et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology 2010;49(7):1367-1373. https://doi.org/10.1093/rheumatology/keq102
33. Lindström U, di Giuseppe D, Delcoigne B, et al. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Ann Rheumat Dis 2021;80(11):1410-1418. https://doi.org/10.1136/annrheumdis-2021-220097
34. Diels J, Thilakarathne P, Schubert A, McElligott S. Comparing efficacy of guselkumab versus ustekinumab in moderate to severe psoriasis patients: An adjusted comparison based on Voyage 1&2 and Navigate Trials. Value Health 2017;20(9):A544-A545.
35. Papp KA, Yang M, Sundaram M, et al. Comparison of adalimumab and etanercept for the treatment of moderate to severe psoriasis: An indirect comparison using individual patient data from randomised trials. Value Health 2018;21(1):1-8. https://doi.org/10.1016/j.jval.2017.05.025
36. Thomas AS. Biologics for the treatment of noninfectious uveitis: Current concepts and emerging therapeutics. Curr Opinion Ophthalmol 2019;30(3):138-150. https://doi.org/10.1097/ ICU.0000000000000562
37. Fragoulis GE, Siebert S. The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis. Musculoskel Care 2022;20:S12-S21. https://doi.org/10.1002/msc.1694
38. Atzeni F, Siragusano C, Masala IF, Carriero A, Picerno V, D’Angelo S. IL-23 in axial spondyloarthritis and psoriatic arthritis: A good fit for biological treatment? Expert Opin Biolog Ther 2022;22(7):843-853. https://doi.org/10.1080/14712598.2022.2090834
39. Kavanaugh A, Puig L, Gottlieb AB, et al. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: Post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Ann Rheumat Dis 2016;75(11):1984-1988. https://doi.org/10.1136/annrheumdis-2015-209068
40. Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: Primary results from a randomised, controlled phase III trial. Arthritis Rheumatol 2019;71(7):1112-1124. https://doi.org/10.1002/art.40851
41. Arvikar SL, Fisher MC. Inflammatory bowel disease associated arthropathy. Curr Rev Musculoskel Med 2011;4:123-131. https://doi.org/10.1007/s12178-011-9085-8
42. Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: A randomised, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006;4(2):203-211. https://doi.org/10.1016/j.cgh.2005.12.002
43. Olivieri I, Cantini F, Castiglione F, et al. Italian expert panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Autoimmunity Rev 2014;13(8):822-830. https://doi.org/10.1016/j.autrev.2014.04.003
44. Cassinotti A, Batticciotto A, Parravicini M, et al. Evidence-based efficacy of methotrexate in adult Crohn’s disease in different intestinal and extraintestinal indications. Therapeut Adv Gastroenterol 2022;15:17562848221085889. Ther Adv Gastroenterol 2022;15:1-30. https://doi.org/10.1177/ 17562848221085889
45. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340(18):1398-1405.
46. Carbonnel F. Methotrexate: A drug of the future in ulcerative colitis? Curr Drug Targets 2011;12(10): 1413-1416. https://doi.org/10.2174/138945011796818252
47. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: Results of the CLASSIC II trial. Gut 2007;56(9):1232-1239. https://doi.org/10.1136/gut.2006.106781
48. Laasila K, Laasonen L, Leirisalo-Repo M. Antibiotic treatment and long term prognosis of reactive arthritis. Ann Rheumat Dis 2003;62(7):655-658.

Click here to access the pdf